Related Experiment Videos
The antineoplastic effects of tuftsin and tuftsinyltuftsin on B16/5B melanoma and L1210 cells
Abstract:
The intraperitoneal (i.p.) injection of tuftsin, Thr-Lys-Pro-Arg, into C57BL/6 mice that were injected with B16/5B melanoma cells, resulted in a considerable suppression and elimination of solid tumor growth. While 100% of control animals exhibited tumor growth, 38% of the treated animals failed to show tumor formation for the duration of the experiment, 60-80 days. The octapeptide, tuftsinyltuftsin, was effective at 3 ng per mouse as was a dose of 2 and 20 micrograms per mouse. In each case there was a significant number of mice free of tumors. The octapeptide was also quite effective against L1210 cells resulting in the survival of 35-40% of the treated animals. The lethal effect of increased superoxide, O X 2, production by tuftsin treatment may explain the antineoplastic effect of the tetrapeptide. This may result not only from higher concentrations of O X 2 but also from the potentially lethal effects of H2O2 and OH X radical, both of which are products of O X 2 metabolism.
Insights
Tuftsin, a peptide, significantly suppressed melanoma and L1210 tumor growth in mice. This peptide treatment led to tumor elimination in some mice and increased survival rates, suggesting potent antineoplastic effects.
Area of Science:
- Immunology
- Biochemistry
- Oncology
Background:
- Tuftsin is a natural tetrapeptide known for its immunomodulatory properties.
- Cancer immunotherapy aims to harness the immune system to fight tumors.
- The antineoplastic effects of tuftsin require further investigation.
Purpose of the Study:
- To evaluate the efficacy of tuftsin and its analog, tuftsinyltuftsin, against B16/5B melanoma and L1210 leukemia in vivo.
- To explore the potential mechanisms behind tuftsin's anti-tumor activity.
Main Methods:
- Intraperitoneal injection of tuftsin and tuftsinyltuftsin into C57BL/6 mice bearing B16/5B melanoma.
- Administration of tuftsin to mice inoculated with L1210 leukemia cells.
- Assessment of tumor growth, tumor elimination, and animal survival rates.
Main Results:
- Tuftsin treatment resulted in significant suppression and elimination of solid B16/5B melanoma tumors, with 38% of treated mice showing no tumor formation.
- Tuftsinyltuftsin demonstrated efficacy at low doses (3 ng/mouse) and higher doses (2-20 µg/mouse), leading to tumor-free animals.
- The octapeptide also showed effectiveness against L1210 leukemia, increasing survival rates to 35-40%.
Conclusions:
- Tuftsin and its analog exhibit potent anti-cancer activity against melanoma and leukemia.
- The anti-tumor effect may be linked to increased superoxide production and its metabolites, contributing to cell death.
- Tuftsin represents a promising therapeutic agent for cancer treatment.